| Patents for A61P 27 - Drugs for disorders of the senses (53,017) |
|---|
| 01/10/2002 | CA2414592A1 Calpain protease 12 |
| 01/10/2002 | CA2414352A1 Method of treating peripheral vascular diseases, peripheral neuropathies, and autonomic neuropathies |
| 01/10/2002 | CA2414347A1 Vaccine comprising active agent immunogenic acyl glyceryl phosphatidylinositol manno-oligosaccharide |
| 01/10/2002 | CA2413243A1 Sulfonyl-pyrrolidine derivatives useful for the treatment of neurological disorders |
| 01/10/2002 | CA2413186A1 Extracellular matrix and cell adhesion molecules |
| 01/10/2002 | CA2413128A1 Transporters and ion channels |
| 01/10/2002 | CA2412872A1 Protein modification and maintenance molecules |
| 01/10/2002 | CA2410953A1 Adenylyl and guanylyl cyclases |
| 01/10/2002 | CA2410945A1 Aryl and heteroaryl diazabicycloalkanes, their preparation and use |
| 01/10/2002 | CA2406649A1 B7-like polynucleotides, polypeptides, and antibodies |
| 01/09/2002 | EP1170373A1 Peptide-mediated ocular cell transfection |
| 01/09/2002 | EP1169475A1 Diagnosis of a person's risk for developing atherosclerosis or diabetic retinopathy |
| 01/09/2002 | EP1169469A1 Human colon cancer associated gene sequences and polypeptides |
| 01/09/2002 | EP1169465A1 Two-step immunization procedure against chlamydia infection |
| 01/09/2002 | EP1169445A2 Human proteins and polynucleotides encoding them |
| 01/09/2002 | EP1169344A1 47 human secreted proteins |
| 01/09/2002 | EP1169334A1 48 human secreted proteins |
| 01/09/2002 | EP1169333A1 49 human secreted proteins |
| 01/09/2002 | EP1169317A1 Triarylimidazoles |
| 01/09/2002 | EP1169306A1 Dibenzoazulene derivatives for treating thrombosis, osteoporosis, arteriosclerosis |
| 01/09/2002 | EP1169061A1 Combination therapy for treating glaucoma |
| 01/09/2002 | EP1169050A1 Ocular treatment using cyclosporin-a derivatives |
| 01/09/2002 | EP1169042A1 Dibenzo-azepine derivatives as alpha v integrin receptor antagonists |
| 01/09/2002 | EP1169038A1 Cyclic protein tyrosine kinase inhibitors |
| 01/09/2002 | EP1169026A2 Use of ap-1 activators to treat glaucoma and ocular hypertension |
| 01/09/2002 | EP1169005A2 Association of no-synthase inhibitor(s) and metabolic antioxidant(s) |
| 01/09/2002 | EP1168917A2 Human lung cancer associated gene sequences and polypeptides |
| 01/09/2002 | CN1330718A Therapeutically active proteins in plants |
| 01/09/2002 | CN1330642A N-[4-(3-chloro-4-fluoro-phenylamino)-7-(3-morpholin-4-yl-propoxy)-quinazolin-6-yl]-acrylamide, irreversible inihibotr of tyrosine kinases |
| 01/09/2002 | CN1330555A Antibodies to truncated VEGF-D and uses thereof |
| 01/09/2002 | CN1330550A Use of substances with oxytocin activity in order to create cell regeneration |
| 01/08/2002 | US6337329 Vision defects and antiinflammatory agents |
| 01/08/2002 | US6337327 Drugs for enzyme inhibiting such as angiotensin converting enzyme |
| 01/08/2002 | US6337325 Combined preparation for the therapy of immune diseases |
| 01/08/2002 | US6337318 Drugs for peptide agonist |
| 01/03/2002 | WO2002000860A2 Novel proteases |
| 01/03/2002 | WO2002000691A2 Polynucleotides and polypeptides encoded thereby |
| 01/03/2002 | WO2002000690A2 Compositions and methods for the diagnosis and treatment of disorders involving angiogenesis |
| 01/03/2002 | WO2002000676A1 Purine derivatives |
| 01/03/2002 | WO2002000658A1 Cyclic gmp-specific phosphodiesterase inhibitors |
| 01/03/2002 | WO2002000656A2 Pirazino '1$m(1)2$m(1) :1, 6! pyrido '3,4-b! indole derivatives |
| 01/03/2002 | WO2002000652A1 Carbamates derived from arylalkylamines |
| 01/03/2002 | WO2002000631A2 Benzhydryl derivatives |
| 01/03/2002 | WO2002000260A1 Remedial agent for optic nerve disease and the like |
| 01/03/2002 | WO2002000245A1 Neurotoxic oligomers |
| 01/03/2002 | WO2002000217A1 Use of 3-substituted oxindole derivatives as kcnq potassium channel modulators |
| 01/03/2002 | WO2002000172A2 Methods for using tetanus toxin for benificial purposes in animals (mammals) |
| 01/03/2002 | WO2002000167A2 Modified forms of pharmacologically active agents and uses therefor |
| 01/03/2002 | WO2002000017A2 Erk-5 deficient animals and methods of inhibiting angiogenesis through the inhibition of erk-5 |
| 01/03/2002 | WO2001071005A3 Multifunctional polypeptides comprising a binding site to an epitope of the nkg2d receptor complex |
| 01/03/2002 | WO2001070693A3 Difluorobutyric acid derivatives and their use as metalloprotease inhibitors |
| 01/03/2002 | WO2001066601A8 Clathrate complexes formed by hyaluronic acid derivatives and use thereof as pharmaceuticals |
| 01/03/2002 | WO2001058472A3 Botulinum toxin pharmaceutical compositions |
| 01/03/2002 | WO2001055336A3 Methods and materials relating to cd84-like polypeptides and polynucleotides |
| 01/03/2002 | WO2001045689A3 Indolinone derivatives for modulation of c-kit tyrosine protein kinase |
| 01/03/2002 | US20020002196 Administering a patient an effective amount of hydroxyeicosatetraenoic acid related compounds to treat the dry eye |
| 01/03/2002 | US20020002191 Fluoroalkoxy-substituted benzamide dichloropyridinyl N-oxide PDE4 inhibitor |
| 01/03/2002 | US20020002150 Cyclopentane(ENE)heptenoic or heptanoic acids and derivatives thereof useful as therapeutic agents |
| 01/03/2002 | US20020002142 Method for identifying and using A2B adenosine receptor antagonists to mediate mammalian cell proliferation |
| 01/03/2002 | DE10028204A1 Verfahren zur Auffindung von medizinisch wertvollen Wirkstoffen Method for identifying medically valuable active ingredients |
| 01/03/2002 | CA2414150A1 Modified forms of nonsteroidal anti-inflammatory drugs and uses thereof |
| 01/03/2002 | CA2413683A1 Fused cyclic compounds as modulators of nuclear hormone receptor function |
| 01/03/2002 | CA2413354A1 Neurotoxic a.beta. oligomers in alzheimer's disease |
| 01/03/2002 | CA2413301A1 Methods for using tetanus toxin for benificial purposes in animals (mammals) |
| 01/03/2002 | CA2412635A1 Novel proteases |
| 01/03/2002 | CA2412256A1 Polynucleotides and polypeptides encoded thereby |
| 01/03/2002 | CA2412211A1 Compositions and methods for the diagnosis and treatment of disorders involving angiogenesis |
| 01/02/2002 | EP1167389A1 Antibodies against the protein SEMP1, methods for their production and uses thereof |
| 01/02/2002 | EP1167357A1 Alpha-substituted carboxylic acid derivatives |
| 01/02/2002 | EP1166801A1 Preparations containing silicon dioxide to improve the taste thereof |
| 01/02/2002 | EP1166788A1 Remedies for joint diseases |
| 01/02/2002 | EP1165784A2 Nucleic acids including open reading frames encoding polypeptides; "orfx" |
| 01/02/2002 | EP1165606A1 50 human secreted proteins |
| 01/02/2002 | EP1165602A1 49 human secreted proteins |
| 01/02/2002 | EP1165591A1 47 human secreted proteins |
| 01/02/2002 | EP1165562A1 Cyclic substituted fused pyrrolocarbazoles and isoindolones |
| 01/02/2002 | EP1165555A2 Aryl fused 2,4-disubstituted pyridines: nk3 receptor ligands |
| 01/02/2002 | EP1165544A1 Substituted 1,4-dihydroindeno[1,2-c]pyrazoles as inhibitors of tyrosine kinase |
| 01/02/2002 | EP1165533A2 Compounds and methods for treatment of asthma, allergy and inflammatory disorders |
| 01/02/2002 | EP1165518A2 Benzimidazole and imidazolopyridine derivatives, their preparation and their use as selective modulators of bradykinin b2 (= bk-2) receptors |
| 01/02/2002 | EP1165500A1 Amide derivatives as inhibitors of matrix metalloproteinases,tnf-alpha,and aggrecanase |
| 01/02/2002 | EP1165490A1 Substituted 2-aminobenzamide caspase inhibitors and the use thereof |
| 01/02/2002 | EP1165143A2 Method for expressing proteins |
| 01/02/2002 | EP1165115A1 Modulation of vascular permeability by mean of tie2 receptor activators |
| 01/02/2002 | EP1165085A1 Phthalazine derivatives for treating inflammatory diseases |
| 01/02/2002 | EP1165084A1 Inhibitors of prenyl-protein transferases |
| 01/02/2002 | EP1165082A1 Inhibitors of prenyl-protein transferase |
| 01/02/2002 | EP1165072A2 Valdecoxib compositions |
| 01/02/2002 | EP1165059A1 Pharmaceutical compositions comprising troponin subunits, fragments and homologs thereof and methods of their use to inhibit angiogenesis |
| 01/02/2002 | EP1165058A2 Use of azalide antibiotics for the topical treatment or prevention of ocular infections |
| 01/02/2002 | EP1165013A2 Inhibitors of prenyl-protein transferase |
| 01/02/2002 | EP1135151A4 Peptoid and nonpeptoid containing alpha-keto oxadiazoles as serine protease inhibitors |
| 01/02/2002 | EP0912553B1 BENZO[g]QUINOLINE DERIVATIVES |
| 01/02/2002 | EP0822829B1 Use of glial neurotrophic factor (gdnf) for treatment of hearing disorders |
| 01/02/2002 | EP0665751B1 Novel 7-(5-substituted cyclopentyl) and (5-substituted cyclopentenyl) heptyl alcohols, heptylamines and heptanoic acid amines, and method of lowering intraocular pressure in the eye of a mammal by administration of these novel compounds |
| 01/02/2002 | CN1329601A New benzimidazolone-benzoxazolone-, or benzothiazolone derivatives as ion channel modulating agents |
| 01/02/2002 | CN1329597A Pyridinium derivatives for treatment of diabetic and aging-related vascular complications |
| 01/02/2002 | CN1329589A N-aralkylaminotetralins as ligands for neuroptide YY5 receptor |
| 01/02/2002 | CN1329505A Composition and method for treating allergic diseases |
| 01/02/2002 | CN1329499A Pharmaceutical preparation containing cyclopeptide and chemotherapeutic agent or angiogenesis inhibitor |